HealthCor Catalio Acquisition Corp. (NASDAQ:HCAQ) announced in an 8-K filing that its shareholders approved its combination with medical technology firms Hyperfine and Liminal Sciences, albeit with high redemptions, at a special meeting yesterday.
A total of 17,142,244 shares were redeemed in connection with the vote, removing about $171.4 million from its estimated trust of $207 million heading into the vote. This should not pose any risk to the transaction’s close, however, as the parties agreed to a $125 million minimum cash condition, which was fully met by the deal’s $126.1 million PIPE, regardless of redemptions.
The deal is expected to close later today and the combined entity is expected to begin trading on the Nasdaq on December 23 under the symbol “HYPR”.
The parties initially announced the $580 million combination on July 8. Hyperfine created the first FDA approved portable MR Imaging System which allows the technology to be accessible at anytime, anywhere, and to any patient. Liminal Sciences is building a device to non-invasively measure key vital signs in the brain to enable unprecedented access to dramatically improve patient outcomes.
All measures on HealthCor’s ballot passed by wide margins but about 23% shares dissented against a number of charter proposals. For full vote tallies, click here.
ADVISORS
- J.P. Morgan is acting as exclusive financial advisor to Hyperfine and Liminal.
- Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is serving as legal advisor to Hyperfine and Liminal.
- Jefferies LLC acted as financial advisor to HealthCor Catalio Acquisition Corp.
- Jefferies LLC and Evercore Group L.L.C. acted as capital markets advisors and co-lead placement agents to HealthCor Catalio Acquisition Corp. in connection with the private placement.
- Wells Fargo Securities also acted as capital markets advisor and placement agent to HealthCor Catalio Acquisition Corp. in connection with the private placement.
- Kirkland & Ellis LLP and Paul Hastings LLP are serving as legal advisors to HealthCor Catalio Acquisition Corp. and the private placement agents.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...